Fig. 6: Inhibitory effect of therapeutic TP53TG1 on pulmonary fibrosis.
From: Systematic analyses identify the anti-fibrotic role of lncRNA TP53TG1 in IPF
a Diagram of the experimental animal model of therapeutic TP53TG1. Mice were intratracheally injected with AAV-TP53TG1 at day five after induction by BLM and sacrificed 21 days later. b Fibrosis markers mRNA level of Fn1, Collagen 1α1, Collagen 3α1, and ACTA2 in lungs after BLM/TP53TG1 treatment. c After fibrosis formation, TP53TG1 inhibited the relative protein expression of Fn1 and Collagen I. d BLM increased hydroxyproline content, which was reversed upon AAV5-TP53TG1 treatment. e CT scans of foci in the lung of mice; n = 3. f Therapeutic TP53TG1 alleviated BLM-induced fibrotic changes in lung tissue detected by H&E and Masson staining; n = 3. g Immunohistochemical staining showed that AAV5-TP53TG1 regulated the expression of Collagen I and α-SMA in lung tissues; n = 3. *P < 0.05; **P < 0.01. AAV-TP53TG1, adeno-associated virus 5 containing TP53TG1; FC fold change.
